Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27

Arthritis Rheumatol. 2014 Feb;66(2):284-94. doi: 10.1002/art.38249.

Abstract

Objective: HLA-B27 and endoplasmic reticulum aminopeptidase 1 (ERAP1) are the two strongest genetic factors predisposing to ankylosing spondylitis (AS). A key aminopeptidase in class I major histocompatibility complex presentation, ERAP1 potentially contributes to the pathogenesis of AS by altering HLA-B27 peptide presentation. The aim of this study was to analyze the effects of ERAP1 on the HLA-B27 peptide repertoire and peptide presentation to cytotoxic T lymphocytes (CTLs).

Methods: ERAP1-silenced and -competent HeLa.B27 and C1R.B27 cells were isotope-labeled, mixed, lysed, and then immunoprecipitated using W6/32 or ME1 antibodies. Peptides bound to HLA-B27 were eluted and analyzed by tandem mass spectrometry. Selected peptides were synthesized and tested for HLA-B27 binding ability. The effect of ERAP1 silencing/mutation on presentation of an immunodominant viral HLA-B27 epitope, KK10, to CTLs was also studied.

Results: In both HeLa.B27 and C1R.B27 cells, the proportion of 9-mer HLA-B27-bound peptides was decreased by ERAP1 silencing, whereas the percentages of longer peptides (11-13 mer) were increased. Surprisingly, following ERAP1 silencing, C-terminally extended peptides were readily identified. These were better able to bind to HLA-B27 than were N-terminally extended peptides lacking an arginine at position 2. In both HeLa.B27 cells and mouse fibroblasts expressing HLA-B27, the absence of ERAP1 reduced peptide recognition by HLA-B27-restricted KK10-specific CTLs following infection with recombinant vaccinia virus or transfection with minigenes expressing KK10 precursors. Presence of an AS-protective variant of ERAP1, K528R, as compared to wild-type ERAP1, reduced the peptide recognition by KK10 CTLs following transfection with extended KK10 minigenes.

Conclusion: These results show that ERAP1 directly alters peptide binding and presentation by HLA-B27, thus demonstrating a potential pathogenic mechanism in AS. Inhibition of ERAP1 could potentially be used for treatment of AS and other ERAP1-associated diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopeptidases / deficiency
  • Aminopeptidases / drug effects
  • Aminopeptidases / genetics
  • Aminopeptidases / metabolism*
  • Animals
  • B-Lymphocytes
  • Cell Line
  • Cells, Cultured
  • Disease Models, Animal
  • Epitopes / genetics
  • Gene Silencing / drug effects
  • HLA-B27 Antigen / metabolism*
  • HeLa Cells
  • Humans
  • Mice, Knockout
  • Minor Histocompatibility Antigens
  • Mutation / genetics
  • Peptides / metabolism*
  • RNA, Small Interfering / pharmacology
  • Spondylitis, Ankylosing / metabolism*
  • Spondylitis, Ankylosing / pathology
  • T-Lymphocytes, Cytotoxic / metabolism
  • T-Lymphocytes, Cytotoxic / pathology

Substances

  • Epitopes
  • HLA-B27 Antigen
  • Minor Histocompatibility Antigens
  • Peptides
  • RNA, Small Interfering
  • Aminopeptidases
  • ERAP1 protein, human
  • ERAP1 protein, mouse